{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Genitourinary+System+Neoplasm", "query": { "condition": "Metastatic Malignant Genitourinary System Neoplasm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 194, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Genitourinary+System+Neoplasm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T23:55:01.676Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer" ], "interventions": [ { "name": "MDNA11", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2021-08-27", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086692" }, { "nct_id": "NCT01305200", "title": "Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "de Novo Myelodysplastic Syndromes", "Disseminated Neuroblastoma", "Juvenile Myelomonocytic Leukemia", "Mucositis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Previously Treated Childhood Rhabdomyosarcoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "supersaturated calcium phosphate rinse", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": 226, "start_date": "2011-03", "completion_date": "2015-06-30", "has_results": true, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 31, "location_summary": "Arcadia, California • Duarte, California • Oakland, California + 26 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01305200" }, { "nct_id": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Advanced Malignant Neoplasm", "Metastatic Cancer", "Metastatic Solid Tumor", "Lung Cancer", "Ovarian Cancer", "Endometrial Cancer", "Prostate Cancer", "Colorectal Cancer", "Breast Cancer", "Other Cancer", "Locally Advanced", "Head and Neck Cancer", "Gall Bladder Cancer", "Small Cell Lung Cancer", "Small Cell Lung Cancer ( SCLC )", "Small Cell Lung Carcinoma", "NSCLC", "NSCLC (Non-small Cell Lung Cancer)", "SCLC", "Non-Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "TNBC", "HER2+ Breast Cancer", "Non-Small Cell Lung Cancer", "ER/PR Positive Breast Cancer", "HER2- Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "ER/PR(+), Her2(-) Breast Cancer" ], "interventions": [ { "name": "rezatapopt", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 300, "start_date": "2020-10-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 33, "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 27 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585750" }, { "nct_id": "NCT01077440", "title": "Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer Survivor", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 24, "start_date": "2010-02", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2014-12-10", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01077440" }, { "nct_id": "NCT05169437", "title": "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Breast Tumor", "Colon Tumor, Malignant", "Lung Tumor", "Urologic Cancer", "Pancreatic Cancer", "Melanoma", "Metastatic Cancer", "Locally Advanced Solid Tumor", "Esophageal Cancer", "Endometrial Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-03-15", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 80, "location_summary": "Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169437" }, { "nct_id": "NCT05958199", "title": "A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm" ], "interventions": [ { "name": "NPX267", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NextPoint Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2023-07-21", "completion_date": "2025-09-20", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 7, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 4 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05958199" }, { "nct_id": "NCT03412877", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Breast Cancer", "Gastrointestinal/Genitourinary Cancers", "Neuroendocrine Tumors", "Multiple Myeloma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Individual Patient TCR-Transduced PBL", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (KEYTRUDA(R))", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 285, "start_date": "2018-09-06", "completion_date": "2029-03-23", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412877" }, { "nct_id": "NCT00667641", "title": "Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2007-03", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2011-05-10", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667641" }, { "nct_id": "NCT00066599", "title": "Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Neutropenia", "Sarcoma" ], "interventions": [ { "name": "voriconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": null, "start_date": "2003-06", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 7, "location_summary": "Orange, California • San Diego, California • Bethesda, Maryland + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066599" }, { "nct_id": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papillomavirus-16 Positive", "Human Papillomavirus-18 Positive", "Metastatic Malignant Neoplasm", "Recurrent Anal Canal Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Penile Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Refractory Malignant Neoplasm", "Stage IV Anal Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8" ], "interventions": [ { "name": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-11-14", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-09-23T23:55:01.676Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439085" } ] }